Key result
Plant sterol and stanol tablets lower LDL-C ~5% compared to placebo.
RCT (n=32)
Placebo-controlled
Randomized crossover
Answers are grounded in this paper and cite their sources.
This randomized, placebo-controlled, crossover trial assessed the lipid-altering efficacy of a dietary supplement (tablet form) providing 1.8 g/day free (non-esterified) plant sterols and stanols versus placebo for 6 weeks as part of a therapeutic lifestyle changes (TLC) diet in 32 men and women with primary hypercholesterolaemia. Mean ± SE baseline (end of a 5-week TLC diet lead-in) lipid concentrations (mmol/l) were total cholesterol (TC), 5.88 ± 0.08; non-high-density lipoprotein cholesterol (non-HDL-C), 4.71 ± 0.09; low-density lipoprotein cholesterol (LDL-C), 4.02 ± 0.08; HDL-C, 1.17 ± 0.06 and triglycerides (TGs), 1.51 ± 0.12. Differences from control in responses (plant sterol/stanol - control) were significant (p < 0.05) for LDL-C ( - 4.9%), non-HDL-C ( - 3.6%) and TC ( - 2.8%). HDL-C and TG responses were not significantly different between treatment conditions. These results indicate that 1.8 g/day free plant sterols/stanols administered in a tablet produced favourable lipoprotein lipid changes in men and women with hypercholesterolaemia.
No takes yet. Share an insight, caveat, or question.
Maki et al. (2011) conducted an RCT in Primary hypercholesterolaemia (n=32). Free (non-esterified) plant sterols and stanols dietary supplement tablet vs. Placebo was evaluated on Lipid concentrations (LDL-C, non-HDL-C, total cholesterol, HDL-C, triglycerides) (MD -4.9% for LDL-C, p=<0.05). Free plant sterols and stanols (1.8 g/day tablet) significantly reduced LDL-C (-4.9%), non-HDL-C (-3.6%), and total cholesterol (-2.8%) versus placebo (p<0.05).
Synapse has enriched 10 related papers. Consider them for comparative context: